Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
Recent evidences support a role of gut microbiota in influencing the efficacy of immune checkpoint inhibitors (ICI). The use of antibiotics (ATB) and other concomitant medications may impair the balance of microbiota and negatively affect the efficacy of immunotherapy.
Retrospective data analysis was performed on advanced cancer patients treated with ICI. Those receiving ATB within 4 weeks before or after initiating ICI were compared with those who did not. Likewise, those who received ATB (irrespective of time of onset) were compared with not exposed and was calculated the variable “ATB exposure” (AE) defined as the % “days of ATB/days of ICI”. Use of proton pump inhibitors (PPIs), opioids and steroids was also evaluated.
Of the 102 patients included, 60 (58.8%) received ATB during immunotherapy treatment (ATB+ group), and 33 (32.3%) received them between 4 weeks before or after starting ICI (ATB4+ group). Median AE of the ATB-treated patients was 11.1% (range 5.6–21.3). PFS and OS did not differ between ATB4+ and ATB4− group or between ATB+ group and not treated one. However, both PFS and OS were significantly lower in patients with a higher AE than the median one (3.1 vs. 8.2 months, p = 0.007; 9.4 vs. 17.8 months, p = 0.02, respectively). PPIs or steroids use did not affect clinical outcome of ICI but opioids use was significantly associated with lower PFS and OS (4.5 vs. 8.1 months, p = 0.010; 8.6 vs. 26.3 months, p < 0.001, respectively).
Cumulative ATB use, rather than simple use in a defined time frame, may impair the efficacy of immunotherapy. Opioids use was also associated with poorer outcomes in patients treated with ICI.
KeywordsGut microbiota Dysbiosis Immune checkpoints inhibitors Antibiotics Opioids Advanced cancer
Immune checkpoint inhibitors
Proton pump inhibitors
The author would like to thank Dr. Manuel Cobo Dols (Medical Oncology Department, Hospital Regional Universitario Málaga and IBIMA, Spain) for his suggestions on study protocol preparation and data collection and Andrés Blanco Hortas (Epidemiology Department, FIDIS, Hospital Lucus Augusti, Lugo, Spain) for his statistical help.
This research did not received any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The author declares no conflict of interest.
The study protocol was approved by the Ethic Committee for Investigation with medicinal products of Galicia (Ref 2019/099) and has been performed in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments.
Due to the retrospective nature of the study, written informed consent was not required. This paper does not contain any individual person’s data in any form.
- 6.Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007;117(8):2197–204. https://doi.org/10.1172/JCI3220.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19(10):848–55.CrossRefGoogle Scholar
- 17.Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rivvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–44. https://doi.org/10.1093/annonc/mdy103.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Huemer F, Rinnerthaler G, Westphal T, Hackl H, Hutarew G, Gampenrieder S, et al. Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget. 2018;9(23):16512–20. https://doi.org/10.18632/oncotarget.24751.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Derosa L, Routy B, Mezquita L, Naltet C, Enot D, Fidelle M, et al. Antibiotics prescription to decrease progression-free survival (PFS) and overall surival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitor. J Clin Oncol. 2017;35(15_suppl):3015.CrossRefGoogle Scholar
- 21.Kim H, Kim I. Clinical association of antibiotics in immune check point inhibitors for advanced cancer treatment. Ann Oncol. 2018;29(suppl_9):ix170–2.Google Scholar
- 24.Kaderbai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab. Anticancer Res. 2017;37:3195–200.Google Scholar
- 27.Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R, Barke RA, Roy S. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS ONE. 2013;8(1):e54040. https://doi.org/10.1371/journal.pone.0054040.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442–65. https://doi.org/10.1007/s11481-011-9292-5.CrossRefPubMedPubMedCentralGoogle Scholar